Andere Sprachen Nevro Corp.

Aktien

A12EPL

US64157F1030

NVRO

Markt geschlossen - Nyse Andere Börsenplätze 22:00:01 24.04.2024			% 5 Tage	% 1. Jan.
12.51 ^USD	-2.19%		-1.50%	-41.87%

15.04.	NEVRO CORP. : RBC Capital Markets gibt neutrale Bewertung ab	ZM
11.04.	NEVRO CORP. : Mizuho Securities bekräftigt seine neutrale Bewertung	ZM

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Nevro to Report First-Quarter 2024 Financial Results and Host Earnings Conference Call on May 7, 2024	17.04.
Non-Opioid Revolution: Beacons of Hope in Opioid Crisis and a $50 Million Spin-Off	09.04.
Nevro Receives FDA 510(k) Clearance to Use SI Fixation System Without Need to Include Lateral Screw	28.02.
Nevro 2024 Sales Expected Slightly Below Estimates, RBC Says	22.02.
Earnings Flash (NVRO) NEVRO Posts Q4 Revenue $116.2M, vs. Street Est of $116M	21.02.
Engaged Capital Enters into Agreement with Nevro Corp	21.02.
Nevro: Q4 Earnings Snapshot	21.02.
Nevro Enters Into Cooperation Agreement With Engaged Capital	21.02.
Nevro Reports Fourth-Quarter and Full-Year 2023 Financial Results	21.02.
Nevro Corp. Appoints Kirt P. Karros to Board of Directors and Audit Committee of the Board	21.02.
Nevro Corp. Provides Earnings Guidance for the First Quarter and Full Year of 2024	21.02.
Nevro Corp. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	21.02.
Nevro to Report Fourth-Quarter and Full-Year 2023 Financial Results and Host Conference Call on February 21, 2024	29.01.
Top 4 Spinal Injury Stocks for 2024 Watchlist (NRX.V, NVRO, SYK, BSX)	23.01.
Top 4 Spinal Injury Stocks for 2024 (NRX.V, NVRO, SYK, BSX)	22.01.
Nevro Announces Positive Coverage Update from Carelon Healthcare for the Treatment of Painful Diabetic Neuropathy	19.01.
Sector Update: Health Care Stocks Mixed in Afternoon Trading	09.01.
Nevro to Cut 5% of Workforce in Restructuring, Says Preliminary Q4 Revenue Rose 2%	09.01.
Nevro Announces Preliminary Fourth-Quarter and Full-Year 2023 Revenue Results	09.01.
Nevro to Present at 42nd Annual J.P. Morgan Healthcare Conference	04.01.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Nevro Corp.

Aktien

A12EPL

US64157F1030

NVRO

Andere Sprachen

Filter